A team of US researchers has developed a new blood test for schizophrenia.
Schizophrenia and related psychotic disorders affect over 3 million people in the US and around 220,000 people in the UK.
The new test identifies biomarkers in the blood that can objectively measure their current severity and future risk for schizophrenia and matches them to treatments that will be most effective for their individual biology.
Senior author Alexander Niculescu, MD, PhD is Professor of Psychiatry and Medical Neuroscience at the Indiana University School of Medicine, staff psychiatrist and investigator at the Richard L. Roudebush Veterans Administration Medical Center in Indianapolis and senior author on the study.
He said: “Schizophrenia is hard to diagnose, especially early on, and matching people to the right treatment from the beginning is very important.
“Psychosis usually manifests in young adulthood — a prime period of life.
“Stress and drugs, including marijuana, are precipitating factors on a background of genetic vulnerability.
“If left unchecked, psychosis leads to accumulating biological damage, social damage and psychological damage.”
In a recent study, researchers tested psychiatric patients that they followed for over a decade.
They identified biomarkers that were predictive of high hallucinations and high delusions states, as well as future psychiatric hospitalisations related to hallucinations and delusions.
The researchers also studied which biomarkers are targets of existing drugs, which enables matching of patients to the right treatments.
The work builds on previous studies over the last two decades by Niculescu and his colleagues on blood biomarkers for other psychiatric disorders (mood disorders, anxiety, post-traumatic stress disorder, suicidality risk, pain and memory disorders).
Niculescu said, in general, the best biomarkers were more predictive than the standard scales used to evaluate someone with hallucinations or delusions, which means the use of this biomarker test can help reduce subjectivity and uncertainty from psychiatric assessments.
The researcher said: “Fortunately, biologically some of the existing medications work quite well if initiated early in the right patients.
“Social support is also paramount, and once that and medications are in place, psychological support and therapy can help as well.
“There is still plenty left to understand and apply about cognition and its abnormalities, but there is reason for optimism in this era of emerging precision psychiatry.”
The test is expected to be available later this year from the Indiana University spin-ou, MindX Sciences.
AI helps cut nuisance alerts for healthcare teams
Stabilising the NHS – it’s going to take a lot more than AI
Answer Digital enables speedy deployment of AI with strategic partnerships
Transforming NHS procurement: How good data holds the key to integrated care
British tech firm gets green light on fibroids patent
Cancer leaders pen ‘letter to the world’ calling for urgent investment
Generative AI used to create translatable paediatric care videos for LMIC hospitals
NHS Forth Valley goes live with RCPCH GrowthAPI integrated with Morse Mobile EPR
Mid and South Essex ICS building new shared care record with Orion Health
Red light can reduce blood glucose levels, study finds
- Medtech3 weeks ago
Medtech leadership insights with Barry Warden
- Diagnostics5 days ago
Thousands with cancer-causing condition offered life-saving NHS bowel cancer test
- Digital health4 weeks ago
Assistance app helps blind and visually impaired commuters find bus stops
- Medtech2 weeks ago
Temperature-sensitive prosthesis improves amputee dexterity and feelings of human connection